Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Rigshospitalet, Copenhagen, Denmark



Survival: 35.7 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: Denmark
   
City/State/Province: Copenhagen
   
Hospital: Rigshospitalet
   
Journal: Link
   
Date: 1/2011

Description:
Patients:
This phase 3 study involved women with advanced breast cancer (genetically HER2-positive) who were divided into two separate treatment groups. Group A consisted of 143 patients with a median age of 56 years. Group B had 141 patients with a median age of 57 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy agent trastuzumab, a monoclonal antibody against the HER2 receptor that interferes with cancer cell growth.

Patients in group B were treated with the chemotherapy agent vinorelbine and the biologic therapy agent trastuzumab.

Toxicities:
Treatment-related death due to infection was reported for group A. Grade 4 neutropenia and grade 3 nerve disorders were also reported.

Treatment-related death due to lung infection and congestive heart failure was reported for group B. Grade 4 neutropenia and grade 3 pain were also reported.

Results:
The median overall survival rates for groups A and B were 35.7 and 38.8 months, respectively.

Support:
This study was supported by the pharmaceutical companies Roche and Sanofi-Aventis.

Correspondence: Dr. Michael Andersson; email: michael.andersson@rh.regionh.dk

E-mail to a Friend Email Physician More Information